Redeye provides a research update following IRLAB's recent Q3 report. While the company reported revenues and a cash position above our estimates, the report did not include any major surprises. We argue that IRLAB's primary focus ahead will be to carry out the upcoming proof-of-concept study with IRL757 and continue its business development efforts regarding mesdopetam and pirepemat.
LÄS MER
